Bayer launches world’s first cannabis-derived prescription drug
Published on 21/06/10 at 11:31am
Sativex is derived from whole plant extracts of the cannabis sativa plant
Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK.
Sativex treats the spasticity symptoms of multiple sclerosis, such as spasms and cramps, and is manufactured with government permission at a secret UK location.
It is the first cannabinoid medicine to be derived from whole plant extracts of the cannabis sativa plant and contain both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Professor John Zajicek, a neurology consultant at Derriford Hospital in Plymouth, said Sativex’s launch was a milestone for cannabinoid medicines.
“Current standard therapy for MS-associated spasticity can produce side effects which patients may find difficult to cope with and not all of them are specifically licensed for spasticity.
“Sativex on the other hand has mainly mild to moderate side effects, which can be easily controlled by adjusting the dose. It has really benefited those people who have found it effective and is a useful addition to available treatments.”
Some 84% of MS sufferers are affected by spasticity, which is caused by damage to those nerves in the central nervous system that carry messages instructing muscles how to move, leading to involuntary muscle over-activity.
Sativex is licensed as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.
It is only available on prescription from a physician with experience in treating MS spasticity and administered by a spray onto the inside of the cheek or under the tongue.
The patient decides how many sprays they need in any one day, with a typical patient taking eight sprays a day from a daily limit of up to 12 sprays.
Sativex’s troubled route to marketDominic Tyer
Mission Statement
InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma jobs, pharma events, and pharma service company listings.
Site content is produced by our editorial team for InPharm.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches.
InPharmjobs.com serves all industry sectors, including: clinical research jobs, pharmaceutical sales jobs, pharma marketing jobs, regulatory affairs jobs, pharmacovigilance jobs, quality assurance jobs, medical affairs jobs, senior management jobs in pharma and drug safety jobs.
---------- Post added at 15:29 ---------- Previous post was at 15:27 ----------
wat je met een
beetje geld en invloed wel niet voor mekaar kan krijgen in deze wereld zeg
Published on 21/06/10 at 11:31am
Sativex is derived from whole plant extracts of the cannabis sativa plant Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK.
Sativex treats the spasticity symptoms of multiple sclerosis, such as spasms and cramps, and is manufactured with government permission at a secret UK location.
It is the first cannabinoid medicine to be derived from whole plant extracts of the cannabis sativa plant and contain both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Professor John Zajicek, a neurology consultant at Derriford Hospital in Plymouth, said Sativex’s launch was a milestone for cannabinoid medicines.
“Current standard therapy for MS-associated spasticity can produce side effects which patients may find difficult to cope with and not all of them are specifically licensed for spasticity.
“Sativex on the other hand has mainly mild to moderate side effects, which can be easily controlled by adjusting the dose. It has really benefited those people who have found it effective and is a useful addition to available treatments.”
Some 84% of MS sufferers are affected by spasticity, which is caused by damage to those nerves in the central nervous system that carry messages instructing muscles how to move, leading to involuntary muscle over-activity.
Sativex is licensed as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.
It is only available on prescription from a physician with experience in treating MS spasticity and administered by a spray onto the inside of the cheek or under the tongue.
The patient decides how many sprays they need in any one day, with a typical patient taking eight sprays a day from a daily limit of up to 12 sprays.
Sativex’s troubled route to marketDominic Tyer
Mission Statement
InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma jobs, pharma events, and pharma service company listings.
Site content is produced by our editorial team for InPharm.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches.
InPharmjobs.com serves all industry sectors, including: clinical research jobs, pharmaceutical sales jobs, pharma marketing jobs, regulatory affairs jobs, pharmacovigilance jobs, quality assurance jobs, medical affairs jobs, senior management jobs in pharma and drug safety jobs.
---------- Post added at 15:29 ---------- Previous post was at 15:27 ----------
wat je met een
beetje geld en invloed wel niet voor mekaar kan krijgen in deze wereld zeg
Comment